Skip to main content
. 2021 Nov 23;81(3):351–358. doi: 10.1136/annrheumdis-2021-221048

Table 4.

Frequently reported TEAEs

Patients, n (%) RZB 150 mg
N=224
PBO
N=219
TEAEs reported in ≥2% of patients in either group
 Upper respiratory tract infection 17 (7.6) 12 (5.5)
 Hypertension 10 (4.5) 6 (2.7)
 Nasopharyngitis 9 (4.0) 8 (3.7)
 Arthralgia 7 (3.1) 7 (3.2)
 Nausea 6 (2.7) 4 (1.8)
 Psoriatic arthropathy 6 (2.7) 9 (4.1)
 Bronchitis 5 (2.2) 4 (1.8)
 Diarrhoea 5 (2.2) 5 (2.3)
 Headache 5 (2.2) 8 (3.7)

PBO, placebo; RZB, risankizumab; TEAE, treatment-emergent adverse event.